Publications by authors named "Patricia A DeFusco"
Purpose: Chemotherapy with or without immunotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC). A subset of TNBCs express the androgen receptor (AR), representing a potential new therapeutic target. This study assessed the feasibility of adjuvant enzalutamide, an AR antagonist, in early-stage, AR-positive (AR +) TNBC.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates chemotherapy-related amenorrhea (CRA) as an indicator of ovarian toxicity and its implications for women's fertility and menopause risks, comparing rates between two treatments: paclitaxel-trastuzumab (TH) and ado-trastuzumab emtansine (T-DM1).
- Patients with early-stage HER2-positive breast cancer from the ATEMPT trial were monitored for menstrual changes over 18 months after receiving either TH or T-DM1, with findings showing a 50% CRA rate in TH recipients compared to 24% in T-DM1 recipients (p=0.045).
- The conclusion emphasizes that T-DM1 is associated with a lower
Article Synopsis
- The study aimed to measure the hemoglobin (Hb) content in breast tumors before starting neoadjuvant chemotherapy, track changes during treatment, and see how these changes correlate with the tumor's response to therapy.
- Patients were monitored using a specialized imaging system over several months, with results graded according to the Miller-Payne system to categorize their response to treatment.
- The findings showed that tumors classified as better responders had higher initial Hb levels and greater changes in Hb content during treatment compared to those classified as non-responders, indicating a potential link between tumor vascularity and treatment effectiveness.